Literatue review demonstrates the cardiotoxicity of anthracyclines on overall ejection fraction and the benefits of proper imaging on reliably capturing cardiac compromise. Review of the literature also demonstrates a lack of knowledge and practice in this area and the negative impact that has on cancer patient's quality of life and survivorship. This event will cover the role of the CardiacOncologist, and the monitoring, management, and surveillance of cancer patients receiving cardiotoxic drugs and the drugs causing cardiotoxicity.
In this one-hour webinar, the presenters will identify the importance of the role of the CardiacOncologist in monitoring and managing oncology patients' cardiac needs. Then provide a pharmacologic review of chemotherapy agents that negatively impact cardiac function, how to educate patients and non-oncology HCPs the importance of cardio toxicity, how cardiac function is best assessed through monitored/best imaging studies, and interventions exist to preserve cardiac function.
Upon attendance of this event, the participant will be able to:
- Understand the role of the subspeciality CardioOncology.
- List antineoplastic agents that have the potential to cause cardiotoxicity.
- Educate patients and peers on importance of surveillance of cardiac function in oncology patients receiving cardiotoxic chemotherapy agents.
- Order the most appropriate cardiac function/imaging test to assess oncology patients' cardiac function.
- Implement cardiac surveillance schedule for patients with cardio toxicity risk.
- List interventions to preserve or intervene to maintain cardiac function.
Target Audience: All members of the cardiac/oncology health care team.
Research:
Since the 1970s, anthracyclines have been known chemotherapeutic agents to treat cancers. In the mid-80s, CardioOncology emerged as a subspeciality bridging the gap between Medical Oncology and Cardiology to prevent cardiovascular disease in cancer patients. Yet as oncology treatments continue to rapidly advance and many antineoplastic drugs compromise cardiac function, many Health Care Professionals (HCP) are not up to date on which medications cause cardiac damage, at what dosage damage can begin to occur, and other comorbidities that can contribute to a compromised cardiac system. In addition, many HCPs are unaware of the CardioOncology subspeciality and the positive implications for the clinical setting.
Research reveals HCPs are not provided regular education to keep them current with the rapid pace of new therapies available to oncology patients combined with a lack of knowledge of the CardioOncology subspecialty. This gap in practice lends itself to patients that are not getting appropriate CardioOncology evaluation with the most current imaging and are not being offered appropriate interventions to mitigate cardiac toxicity of many antineoplastic agents. Many HCPs are relying on dated assessment tools (2D Echo) to evaluate the heart leading to under identification of patients with cardio toxicity leading to more patients with heart failure than is necessary.
Presenters:
Patricia Guerro, MD, FACC, is a board certified Clinical Cardiac Electrophysiologist and Clinical Cardiologist with AdventHealth Medical Group (previously Florida Heart Group). She is the Medical Director of the Women and Heart Disease Program of the Cardiovascular Institute at Advent Health. She is also the Physician Lead for the Advent Health Cardiovascular Institute Cardio-Oncology program, Cardiovascular Genomics program and Cardiovascular Wellness program. Dr. Guerrero is the Medical Advisory Committee chair for the Winter Park Center for Health and Wellbeing and the Physician Education Chairperson for the CV Genomics community program for Familial Hyperlipidemia. Prior to joining AdventHealth in 2002, she completed her Cardiovascular and EP fellowship at Washington University and was an Associate with Missouri Cardiovascular Specialist in Columbia, Missouri. Her main clinical interests are the prevention and early identification of heart disease, Cardio-oncology, and the evaluation of patients with arrhythmias. Her principal research interests include cardiovascular population health; and cardiac device therapies for the management of fatal cardiac arrhythmias and heart failure.
Janet Celli BSN, RN, PCCN grew up in Massachusetts where she obtained her BSN from Boston University. She began he career as a staff nurse in an ICU setting caring for Surgical Oncology patients. Janet was a travel nurse for 2 years prior to signing on with Florida Hospital Orlando Cardiovascular Institute where she quickly accepted the role of Assistant Nurse Manager on the post Cardiothoracic Surgical Stepdown unit. As a leader Janet excelled in driving the team toward excellence, helped the staff build confidence through national certification by offering classes in assertive communication and preparation to sit for the PCCN exam. In 2002 she co-founded CPR Associates of America, an American Heart Association (AHA) training site with the mission to teach life saving skills to the public and development of widespread Public Access Defibrillation programs. Each year approximately 1200 students are trained in CPR/AED, BLS, ACLS, First Aid, and Stop the Bleed. Janet has been a spokesperson for the AHA in heart disease, stroke, and resuscitation and has presented at the National Teaching Institute for the American Association of Critical-Care Nurses as well as for the local Metropolitan Orlando Chapter. In 2019 Janet accepted a new position as the Cardio Oncology and Genomics Nurse Navigator, a role she has embraced and fully enjoys. Beyond her passion for nursing Janet loves traveling and enjoying outside activities such as hiking, biking, golfing, and running.
Stephen J. Caselli is the Executive Director of the International Cardio-Oncology Society (IC-OS). IC-OS is a fast growing professional society devoted to supporting all those who touch cardio-oncology patients. IC-OS is also developing a patient advocacy network. Having been raised in Columbus, OH he is a diehard Buckeye fan. Steve and his wife Missy live in Tampa, FL and have three children and one grandson.
|